Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Clinical trial NCT06008756 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06008756
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Arteriosclerosis Hypercholesterolaemia

Start date: 2023-10-09
Primary completion: 2029-11-29
Enrollment: 14550

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.